You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 First-line treatment regimens

From: Development and validation of a prognostic scoring model for Mycobacterium avium complex lung disease: an observational cohort study

  Cohort 1 Cohort 2
Patients who received treatments 169 (100.0) 66 (100.0)
 CAM + EB + RFP 134 (79.3) 39 (59.1)
 CAM + RFP 30 (17.8) 6 (9.1)
 CAM + EB + RFP + SM 2 (1.2) 2 (3.0)
 CAM + EB 1 (0.6) 6 (9.1)
 CAM + RFP + NQ 1 (0.6) 5 (7.6)
 CAM + EB + NQ 0 (0.0) 2 (3.0)
 CAM + EB + RFP + NQ 0 (0.0) 2 (3.0)
 Other regimens 1(0.6) 4 (6.1)
  1. Data are n (%)
  2. CAM clarithromycin, RFP rifampicin, EB ethambutol, SM streptomycin, NQ new quinolones